Statistics for GAPDH measurement.
| Comparisons | Samples | Mean diff. | 95.00% CI of diff. | p-Value | p-Value (pairing)1 |
|---|---|---|---|---|---|
| Peptide vs. vehicle—30 yo | 15 vs. 15 | 16.37 | 9.69 to 23.05 | 0.0001 | < 0.0001 |
| Peptide vs. vehicle—70 yo (a) | 27 vs. 27 | 38.59 | 16.97 to 60.21 | 0.0011 | 0.0262 |
| DMSO vs. inhib2 | 18 vs. 18 | –57.10 | –77.49 to –36.72 | < 0.0001 | NA3 |
1: Significance levels for effective pairing; 2: significant difference of variances (p = 0.0099); 3: NA = not applicable; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; 30 yo: 30-year-old; 70 yo: 70-year-old; DMSO: dimethyl sulfoxide; inhib: inhibitor; diff.: difference.
The author gratefully acknowledges the support of the Marion Murray Spinal Cord Research Center at the Department of Neurobiology and Anatomy, Drexel University College of Medicine, and Center manager Theresa Connors for expert technical assistance.
TJC: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Validation, Visualization, Writing—original draft, Writing—review & editing. The author read and approved the submitted version.
Drexel University and the author have applied for patent protection of the peptide compound that is the subject of this paper. Partial financial support was provided by CHEC-PR LLC, a company established to develop peptide therapies. The company had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
BioIVT provides viral-negative normal human blood products collected from consented donors under Seratrials LLC IRB protocol #2010-017 approved by WCG (WIRB-Copernicus Group), expiring 9/07/2026.
Informed consent to participate in the study was obtained from all participants.
Not applicable.
All data sets and limited samples of cSKE7 peptide for independent testing are available at no cost to qualified research laboratories. Please contact Timothy Cunningham at tjc29@drexel.edu.
Partial financial support was provided by the Department of Neurobiology & Anatomy, Drexel University College of Medicine, and by CHEC-PR LLC, a company established to develop peptide therapies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.